BioSpace News Archive

Oncorena AB announces that the Board of Directors of Oncorena AB has appointed Professor Börje Haraldsson as CEO of the company, effective as of . He thus succeeds Dr. Lars Grundemar, who will leave the company.

Pharnext SA announces that at its Annual General Meeting on Friday June 17th all key resolutions proposed by the Pharnext Board of Directors were adopted.

Dxcover Limited, a clinical stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, announced the launch of the Dxcover® platform, a ground-breaking platform that transforms Attenuated Total Reflectance Fourier Transform Infrared spectroscopy to enable faster sample analysis.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), announced today positive 2-month interim results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD.

Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation (CV) study.

assisTek, based in Doylestown, PA , has announced its latest partnership with Philadelphia based Strados Labs.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix.

Sen-Jam Pharmaceutical names thought leader and scientific innovator Dr. Alex Wissner-Gross to its Advisory Board.

3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology.

Ultragenyx’s continued support bolsters n-Lorem’s non-profit model to provide personalized investigational medicines to nano-rare patients.